Ophthalmology – Retinal Vasoproliferative Tumor

Basics

Description

A retinal vasoproliferative tumor (VPT) is a benign peripheral retinal mass characterized by a mixture of:

• Reactive glial proliferation
• Abnormal retinal vascular proliferation
• Chronic exudation

Despite its name, VPT is now better regarded as a:

Reactive gliovascular proliferation rather than a true vascular neoplasm.

Typical features include:

• Yellow-pink to yellow-red retinal mass
• Peripheral location
• Relatively inconspicuous feeding vessels
• Intraretinal/subretinal lipid exudation
• Macular edema or epiretinal membrane in more advanced cases

VPT may be:

• Primary/idiopathic
• Secondary to another ocular disorder

Key Clinical Pattern

The classic lesion is:

A solitary yellow-pink inferotemporal peripheral retinal mass with prominent exudation but without the markedly dilated feeder arteriole and draining vein characteristic of retinal hemangioblastoma.

The major threat to vision is usually not the mass itself, but secondary:

• Macular edema
• Lipid exudation
• Epiretinal membrane
• Exudative retinal detachment
• Vitreoretinal traction

Terminology

Older names include:

• Presumed acquired retinal hemangioma
• Angioma-like retinal mass
• Peripheral retinal telangiectasia
• Reactionary retinal glioangiosis

The preferred term remains:

Retinal vasoproliferative tumor

although histopathology supports a predominantly reactive gliotic process.

Epidemiology

VPT is uncommon.

Typical patients are:

• Adults
• Often middle-aged

There is no strong:

• Sex predilection
• Racial predilection

Most primary lesions are:

• Unilateral
• Solitary

Secondary lesions are more likely to be:

• Multiple
• Bilateral
• Associated with chronic retinal disease

Classification

Primary VPT

Also called:

Idiopathic VPT

No underlying ocular disorder is identified.

These are commonly:

• Solitary
• Unilateral
• Inferotemporal

Secondary VPT

Secondary tumors develop in association with chronic retinal inflammation, degeneration, or injury.

Important associations include:

• Retinitis pigmentosa
• Intermediate uveitis
• Toxoplasma chorioretinitis
• Ocular toxocariasis
• Retinochoroidal coloboma
• Chronic retinal detachment
• Prior retinal surgery
• Ocular trauma
• Other chronic inflammatory or degenerative retinopathies

Pathophysiology

Histopathology demonstrates predominantly:

• Reactive glial proliferation
• Telangiectatic retinal vessels
• Fibrosis
• Lipid exudation
• Chronic inflammatory cells

This supports the concept that VPT represents:

Reactive retinal gliosis with secondary vascular proliferation

rather than a primary angiomatous tumor.

Genetics

There is:

No established hereditary mutation responsible for VPT.

Routine genetic testing is not indicated.

If the lesion instead resembles a:

Retinal hemangioblastoma

particularly in a young patient with:

• Multiple lesions
• Bilateral lesions
• Markedly dilated feeder vessels
• Family history

then evaluation for von Hippel-Lindau disease may be appropriate.

Clinical Presentation

Patients may be:

• Asymptomatic
• Mildly symptomatic
• Visually impaired

Common symptoms include:

• Blurred vision
• Floaters
• Metamorphopsia
• Photopsias
• Peripheral field disturbance

Visual symptoms usually reflect:

• Macular edema
• Epiretinal membrane
• Exudation
• Retinal detachment

rather than direct involvement of the peripheral tumor.

Visual Acuity

Many patients retain good visual acuity at diagnosis.

Vision becomes impaired when there is:

• Foveal edema
• Macular lipid
• Epiretinal membrane
• Macular traction
• Retinal detachment
• Vitreous hemorrhage

Fundus Appearance

A VPT typically appears as:

A yellow-white, yellow-pink, or yellow-red elevated retinal mass

with:

• Ill-defined or moderately defined borders
• Surface telangiectasia
• Surrounding exudation

Location

The classic site is:

Inferotemporal peripheral retina

usually between:

• Equator
• Ora serrata

Other quadrants may be involved.

Size

Most lesions are:

• Relatively small
• A few millimeters in diameter

Thickness varies and becomes clinically important when selecting treatment.

Feeding Vessels

Unlike retinal hemangioblastoma, VPT typically has:

• Normal or only mildly dilated feeding vessels
• Little vascular tortuosity

This is an important diagnostic clue.

Associated Retinal Findings

Common findings include:

• Intraretinal lipid exudation
• Subretinal exudation
• Retinal edema
• Macular edema
• Epiretinal membrane
• Preretinal fibrosis
• Exudative retinal detachment

Hemorrhagic Findings

Less commonly:

• Intraretinal hemorrhage
• Subretinal hemorrhage
• Vitreous hemorrhage

may occur.

Vitreoretinal Fibrosis

Fibroglial proliferation may lead to:

• Epiretinal membrane
• Retinal folds
• Macular traction
• Tractional retinal detachment

This is especially important in longstanding lesions.

Anterior Segment Findings

Secondary ocular findings may include:

• Cataract
• Anterior vitreous cells
• Posterior synechiae
• Elevated IOP

These are more likely when VPT occurs with chronic inflammatory disease.

Diagnosis

Diagnosis is generally based on:

• Clinical appearance
• Peripheral retinal examination
• Multimodal imaging

The principal diagnostic challenge is distinguishing VPT from:

• Retinal hemangioblastoma
• Choroidal melanoma
• PEHCR
• Other peripheral retinal/choroidal masses

Wide-Field Fundus Photography

Useful for:

• Documenting tumor size
• Location
• Exudation
• Serial comparison

Wide-field imaging is particularly helpful because lesions are usually:

Far peripheral.

Fluorescein Angiography

FA may show:

• Early filling of intralesional vessels
• Telangiectatic vascular pattern
• Late diffuse leakage

However, the vascular pattern is usually less dramatic than in retinal hemangioblastoma.

FA in Retinal Hemangioblastoma vs VPT

VPT

• Mild or no feeder vessel enlargement
• Diffuse vascular leakage
• Strong exudative component

Retinal Hemangioblastoma

• Prominent dilated feeding arteriole
• Prominent draining vein
• Dense intrinsic capillary network
• Intense late leakage

OCT

Macular OCT is extremely useful for detecting complications including:

• Cystoid macular edema
• Subretinal fluid
• Hard exudates
• Epiretinal membrane
• Vitreomacular traction

OCT often guides whether treatment is necessary.

Peripheral OCT

Wide-field or peripheral OCT, when technically possible, can help characterize:

• Retinal origin of the lesion
• Gliotic component
• Surface fibrosis
• Associated exudation

Ultrasonography

B-scan ultrasonography may demonstrate:

• Elevated peripheral mass
• Medium to high internal reflectivity

It can help distinguish VPT from:

• Choroidal melanoma

but small peripheral lesions can be difficult to image reliably.

Ultrasound Features

VPT generally shows:

• Acoustic solidity
• Moderate/high reflectivity
• No classic choroidal excavation

A low-reflective solid choroidal mass should raise greater concern for:

Melanoma.

Indocyanine Green Angiography

ICGA may show:

• Intralesional vascularity
• Late hyperfluorescence

Its role is supplementary rather than essential.

Systemic Testing

Routine systemic testing is:

Not required for a typical primary VPT.

Investigations should instead target suspected underlying disease in secondary cases.

Secondary VPT Work-Up

Depending on clinical context, investigate for:

• Uveitis
• Retinitis pigmentosa
• Previous infectious retinitis
• Chronic retinal detachment
• Trauma
• Prior retinal surgery

Testing should be:

Directed by the suspected underlying disorder

rather than performed as a universal panel.

VHL Testing

Routine VHL genetic testing is:

Not indicated for typical VPT.

Consider VHL evaluation only if clinical findings suggest:

• Retinal hemangioblastoma rather than VPT
• Multiple vascular tumors
• Bilateral disease
• Strong family/systemic history

Differential Diagnosis

Important differentials include:

• Retinal hemangioblastoma
• Choroidal melanoma
• Peripheral exudative hemorrhagic chorioretinopathy
• Retinal cavernous hemangioma
• Coats disease
• Retinal macroaneurysm
• Choroidal granuloma
• Retinal detachment-associated gliosis

VPT vs Retinal Hemangioblastoma

This is the key differential.

Vasoproliferative Tumor

• Usually yellow-pink
• Inferotemporal
• Minimal feeder vessel enlargement
• Prominent exudation
• Reactive gliovascular lesion
• No routine VHL association

Retinal Hemangioblastoma

• Orange-red vascular mass
• Prominent feeder arteriole
• Prominent draining vein
• Strong FA leakage
• May be multiple/bilateral
• Strong association with VHL

VPT vs Choroidal Melanoma

VPT

• Retinal rather than choroidal origin
• Yellow-pink
• High/medium ultrasound reflectivity
• Exudation prominent
• Usually small peripheral lesion

Melanoma

• Choroidal origin
• Often pigmented
• Lower internal reflectivity
• Possible orange pigment
• Possible acoustic hollowness

Any uncertain peripheral mass warrants:

Ocular oncology assessment.

VPT vs PEHCR

Peripheral exudative hemorrhagic chorioretinopathy (PEHCR) usually occurs in:

• Older adults

and may show:

• Peripheral subretinal/sub-RPE hemorrhage
• Exudation
• Fibrosis

PEHCR is primarily a:

Choroidal/RPE hemorrhagic disorder

rather than a retinal gliovascular mass.

Treatment Principles

Treatment depends on:

• Symptoms
• Tumor size
• Exudation
• Macular involvement
• Retinal detachment
• Secondary traction

Not every VPT requires treatment.

Observation

Observation is appropriate when the lesion is:

• Small
• Asymptomatic
• Stable
• Without vision-threatening exudation
• Without progressive retinal detachment

Serial evaluation should document:

• Tumor size
• Exudation
• Macular OCT

Indications for Treatment

Treatment is generally considered when there is:

• Macular edema
• Foveal-threatening exudation
• Progressive subretinal fluid
• Exudative retinal detachment
• Progressive tumor activity
• Vitreoretinal traction
• Visual loss

Cryotherapy

Cryotherapy is a principal treatment for peripheral VPT.

It is particularly useful because most lesions are located:

• Near the ora
• In the far peripheral retina

The goal is:

• Tumor involution
• Reduction in vascular leakage
• Resolution of exudation

Cryotherapy Technique

Treatment often requires:

• Double freeze-thaw applications

and may require:

• More than one session

depending on lesion size and response.

Cryotherapy Limitations

Cryotherapy causes inflammation and can temporarily worsen:

• Exudation
• Macular edema
• Subretinal fluid

Therefore large or highly exudative lesions require:

Careful staged treatment and monitoring.

Laser Photocoagulation

Laser may be considered for:

• Smaller lesions
• More posterior tumors
• Lesions accessible to laser

It is less useful for:

• Thick lesions
• Very peripheral lesions
• Lesions obscured by exudation

Photodynamic Therapy

Photodynamic therapy (PDT) can be effective for selected:

• Posterior
• Moderately sized
• Exudative lesions

It may be particularly useful when conventional laser or cryotherapy would damage surrounding structures.

Plaque Brachytherapy

Plaque radiotherapy can be considered for:

• Large or thick VPT
• Extensive exudation
• Exudative retinal detachment
• Lesions refractory to cryotherapy/laser

Radioactive plaque treatment can produce:

• Tumor regression
• Reduced exudation
• Retinal reattachment

Anti-VEGF Therapy

Intravitreal anti-VEGF may reduce:

• Macular edema
• Retinal exudation
• Subretinal fluid

Agents include:

• Bevacizumab
• Ranibizumab
• Aflibercept

However:

Anti-VEGF does not reliably eliminate the underlying VPT.

It should generally be regarded as:

Adjunctive therapy rather than definitive monotherapy.

Corticosteroids

Intravitreal or periocular corticosteroid may be useful for:

• Significant macular edema
• Inflammatory secondary VPT
• Exudation accompanying definitive therapy

Potential risks include:

• Cataract
• Elevated IOP
• Infection

Combined Therapy

A commonly useful strategy for highly exudative lesions is:

Definitive tumor ablation + adjunctive anti-VEGF or corticosteroid

to address associated macular edema or subretinal fluid.

Vitrectomy

Pars plana vitrectomy may be indicated for complications such as:

• Nonclearing vitreous hemorrhage
• Epiretinal membrane with visual distortion
• Tractional retinal detachment
• Combined tractional/exudative retinal detachment
• Severe vitreoretinal fibrosis

Epiretinal Membrane

ERM is an important cause of reduced vision in VPT.

When visually significant, management may require:

Vitrectomy with membrane peeling

once the active peripheral lesion has been controlled.

Retinal Detachment

Exudative retinal detachment may resolve after:

• Effective tumor treatment

More complex detachments with traction may require:

• Vitrectomy
• Membrane dissection
• Other retinal surgical techniques

Local Tumor Resection

Surgical excision has occasionally been performed for:

• Large
• Refractory
• Diagnostically uncertain lesions

but is technically challenging and:

Not routine first-line management.

Enucleation

Enucleation is now:

Extremely uncommon

and should be reserved for situations such as:

• Blind painful eye
• Severe uncontrolled secondary glaucoma
• End-stage untreatable disease
• Rare unresolved concern for malignancy

Management of Secondary VPT

When VPT is secondary, also treat the underlying condition.

Examples:

Intermediate Uveitis

• Control ocular inflammation

Retinitis Pigmentosa

• Manage associated CME and retinal complications

Infectious Chorioretinitis

• Treat active infection if present

Chronic Retinal Detachment

• Address detachment where appropriate

Failure to control the underlying disease may promote continued retinal reactivity.

Follow-Up

Follow-up depends on:

• Activity
• Exudation
• Macular involvement
• Treatment modality

Stable asymptomatic lesions may be followed approximately:

Every 6–12 months

Active or recently treated lesions require closer follow-up.

Monitoring

Assess:

• Visual acuity
• Tumor size
• Exudation
• Subretinal fluid
• Macular edema
• Epiretinal membrane
• Retinal detachment

Use serial:

• Wide-field photography
• OCT

as appropriate.

Prognosis

Overall prognosis is generally:

Good when disease is recognized before permanent macular damage occurs.

Many small lesions remain stable.

Causes of Poor Vision

Permanent visual loss may result from:

• Chronic macular edema
• Foveal hard exudates
• Macular fibrosis
• Epiretinal membrane
• Tractional damage
• Longstanding retinal detachment

Primary vs Secondary Prognosis

Primary solitary VPT often has:

• Favorable prognosis

Secondary disease may be more complicated because of:

• Bilaterality
• Multiple tumors
• Underlying retinal degeneration
• Chronic inflammation
• Preexisting visual impairment

Complications

Potential complications include:

• Macular edema
• Hard exudates
• Exudative retinal detachment
• Epiretinal membrane
• Preretinal fibrosis
• Tractional retinal detachment
• Vitreous hemorrhage
• Cataract
• Secondary glaucoma
• Permanent visual loss

Ophthalmology Pearls

• Retinal vasoproliferative tumor is better regarded as a reactive gliovascular proliferation than a true vascular neoplasm.
• The classic lesion is a yellow-pink peripheral retinal mass, usually inferotemporal, with prominent exudation and only mildly abnormal feeding vessels.
• VPT may be primary/idiopathic or secondary to conditions such as retinitis pigmentosa, intermediate uveitis, previous chorioretinitis, chronic retinal detachment, or trauma.
• Secondary VPT is more likely to be multiple or bilateral.
• The principal visual threats are macular edema, lipid exudation, epiretinal membrane, and exudative or tractional retinal detachment.
• The most important differential is retinal hemangioblastoma.
• RHB has a conspicuous dilated feeder arteriole and draining vein, whereas VPT typically has relatively inconspicuous feeder vessels.
• VPT has no established VHL association, and routine VHL genetic testing is unnecessary unless the diagnosis actually suggests retinal hemangioblastoma.
• Wide-field photography documents the peripheral lesion; OCT is especially important for detecting macular edema, subretinal fluid, and epiretinal membrane.
• On FA, VPT demonstrates intrinsic vascular filling with late leakage, but usually without the striking feeder-vessel pattern of RHB.
• Observation is appropriate for small, stable, asymptomatic lesions without vision-threatening exudation.
• Cryotherapy is a principal treatment for symptomatic peripheral VPT because most tumors are located near the equator or ora serrata.
• Laser or PDT can be useful for selected more posterior lesions.
• Plaque brachytherapy is an important option for large, thick, highly exudative, or treatment-resistant tumors.
• Anti-VEGF and corticosteroids may reduce macular edema and exudation, but are generally adjuncts rather than definitive treatment of the tumor.
• Vitrectomy is reserved for complications such as nonclearing vitreous hemorrhage, significant epiretinal membrane, or tractional retinal detachment.
• The long-term visual outcome depends more on the degree of macular damage and vitreoretinal fibrosis than on the size of the peripheral tumor itself.